The biotech industry in Asia is a promising market, but it still has a long way to go to narrow the gap between Asian and Western markets, according to speakers on day two of the BIO Asia-Taiwan Conference 2021.
Financing is the fuel that drives growth in the biopharma sector, and participants at the BIO Asia-Taiwan Conference 2021 this week discussed different financing strategies for companies in the currently booming market.
Data presented at The International Liver Congress – The Annual Meeting of the European Association for the Study of the Liver, including: Brii Biosciences, VBI Vaccines.
Sometimes, scientific progress comes from conceptual insights that arrive in a flash. More often, however, such progress arrives in a decidedly less glamorous, though no less important, manner.
Beigene Ltd. unveiled positive interim results from its Alpine phase III trial comparing its small-molecule BTK inhibitor, Brukinsa (zanubrutinib), to Abbvie Inc.’s Imbruvica (ibrutinib), lending validity to one of the company’s most important development programs.
With Pharmabcine Inc.’s anti-angiogenic antibody TTAC-0001 (olinvacimab) already in testing against recurrent glioblastoma multiforme (GBM) and metastatic triple negative breast cancer, CEO Jin-San Yoo is now giving serious thought to starting trials to test it in children with brain tumors. Plans to begin four additional trials between the end of 2021 and the beginning of 2022 are also underway.
At the 2021 virtual annual meeting of the American Society for Clinical Oncology (ASCO), results of the VISION trial testing the addition of Novartis AG’s radiopharmaceutical Lutetium-177-PSMA-617 (Lutetium-PSMA) to individualized standard-of-care regimens in metastatic castration-resistant prostate cancer improved both overall survival and radiographic progression-free survival.
RSS
